Clinical Trial Protocol
Iranian Registry of Clinical Trials

06 Jun 2026

The effect of Pentoxifylline on C reactive protein level and dialysis adequacy in end stage renal disease patients under hemodialysis

Protocol summary

Summary

purpose of study: The effect of pentoxifylline on C reactive protein level (an acute phase reactant) and dialysis adequacy in end stage renal disease patients under hemodialysis structure of study: randomized, double blind,control with placebo Patients referred to dialysis institute of Valiasr Hospital after matching for Age, Sex and Time that patients were under dialysis, randomly sent in two groups of drug and placebo. Patients and dialysis institute staff were not aware of which group is drug group and which one is placebo group. inclusion criteria: acceptance of written consent; End Stage Renal Disease; more than 15year; BMI between 15 - 35 exclusion criteria: pentoxifylline use before study; no acceptance of written consent; abnormal LFT; hyper sensitivity reaction to pentoxifylline; active infection; recent malignancy; depression; recent ICH; recent retinal hemorrhage;dialysis period under 3 month. population of study: end stage renal disease patients under hemodialysis referred to Valiasr hospital. number of population of study: 80 patients. intervention of study: The effect of pentoxifylline on C reactive protein level (an acute phase reactant) and dialysis adequacy time of study: one month consumption of Pentoxifylline primary results: decrease in serum CRP level and increase in dialysis adequacy

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013120715695N1**
Registration date: **2014-01-28, 1392/11/08**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2014-01-28, 1392/11/08

Registrant information

Name
Pardis ketabi Moghaddam
Name of organization / entity
Amiralmomenin hospital
Country
Iran (Islamic Republic of)
Phone
+98 86 3417 3601
Email address
dr.ketabimoghadam@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Arak University of Medical Sciences

Expected recruitment start date

2014-03-21, 1393/01/01

Expected recruitment end date

2015-02-20, 1393/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of Pentoxifylline on C reactive protein level and dialysis adequacy in end stage renal disease patients under hemodialysis

Public title

The effect of Pentoxifylline on C reactive protein level and dialysis adequacy

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: acceptance of written consent; End

Stage Renal Disease; more than 15year; BMI between 15 - 35 Exclusion criteria: pentoxifylline use before study; no acceptance of written consent; abnormal LFT; hyper sensitivity reaction to pentoxifylline; active infection; recent malignancy; depression;recent ICH; recent retinal hemorrhage; dialysis period under 3 months

Age
From **15 years** old

Gender
Both

Phase
3

Groups that have been masked
No information

Sample size
Target sample size: **80**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Arak University of Medical Sciences

Street address
Pardis Site, Bbasij Square, Arak

City
Arak

Postal code
3848176941

Approval date
2013-09-23, 1392/07/01

Ethics committee reference number
92-148-12

Health conditions studied

1

Description of health condition studied
esrd

ICD-10 code
N18.5

ICD-10 code description
Chronic kidney Disease, stage 5

2

Description of health condition studied
Ischemic Heart Disease

ICD-10 code
120-125

ICD-10 code description
Angina pectoris, Acute myocardial infarction, Subsequent myocardial infarction, Certain current complications following acute myocardial infarction, Other acute ischaemic heart diseases, Chronic ischaemic heart disease,

Primary outcomes

1

Description
CRP

Timepoint
before and after receiving placebo or drug

Method of measurement
quantitative kit of CRP

Secondary outcomes

1

Description
Dialysis Adequacy

Timepoint
before and after dialysis and before and after receiving placebo or drug

Method of measurement
KT/V: K (cc/min) x time (min) / urea volume (cc)

Intervention groups

1

Description
Pentoxifylline Tab 400 mg daily 30 days in Intervention group

Category
Treatment - Drugs

2

Description
Starch Tab daily in Control group

Category
Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center
Dialysis Institute of Valiasr Hospital

Full name of responsible person
Pardis Ketabi Moghaddam

Street address
Valiasr Hospital, Sardaran Square, Arak
City
Arak

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Arak University of Medical Sciences
Full name of responsible person
Miss Jahani
Street address
Research and Education Site, Arak Medical University, Basij Square, Arak
City
Arak
Grant name
Grant code / Reference number
933
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Arak University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Amiralmomenin Hospital
Full name of responsible person
Dr. Afsaneh Talayi
Position
Internist, Endocrinologist
Other areas of specialty/work
Street address
Amiralmomenin Hospital, Basij Square, Arak
City
Arak
Postal code
3848176941
Phone
+98 86 3417 3601
Fax
+98 34173630
Email
amoozesh@arakmu.ac.ir
Web page address
http://www.arakmu.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Amiralmomenin Hospital
Full name of responsible person
Dr Parvin Soltani
Position
Nephrologist
Other areas of specialty/work
Street address
Amiralmomenin Hospital, Basij Square, Arak
City
Arak
Postal code
3848176941
Phone
+98 86 3417 3601
Fax
+98 34173630
Email
dr.ketabimoghadam@arakmu.ac.ir
Web page address
http://www.arakmu.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Amiralmomenin Hospital
Full name of responsible person
Dr Pardis Ketabi Moghaddam
Position
Internal Medicine Assistant
Other areas of specialty/work
Street address
Amiralmomenin Hospital, Basij Square, Arak
City
Arak
Postal code
3848176941
Phone
+98 86 3417 3601
Fax
+98 34173630
Email
dr.ketabimoghadam@arakmu.ac.irgh_nyx@yahoo.ac.in
Web page address
http://www.arakmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty

Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty